Insider Transactions Reported by 28 Insiders of Q32 Bio Inc.

Symbol: QTTB on Nasdaq
Location: Waltham, MA

Quick Takeaways

QTTB - Q32 Bio Inc. has 28 insiders with reported activity on this page.
Net insider value flow over the last year: -$216,605.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: ; sell value: $216,604.
Net share flow: -66,008.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$216,605.

Buys

Shares: 0

Insiders: 0

Sells

$216,605

Shares: 66,008

Insiders: 3

Net

-$216,605

Shares: -66,008

Insiders: -3

Window (months)	Sell shares	Buy $	Sell $	Net $
0-3	16,706	$0	$75,418	-$75,418
3-6	31,578	$0	$109,266	-$109,266
6-9	17,724	$0	$31,921	-$31,921
9-12	0	$0	$0	$0

Q32 Bio Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
W. Bradford Smith	Chief Financial and Business Officer and Treasurer	$2,899,867			Mixed	23 Feb 2023
Michael L. Blum	Chief Commercial Officer	$1,415,233			Mixed	23 Feb 2023
ORBIMED ADVISORS LLC	Director, 10%+ Owner	$1,286,681			Mixed	25 Mar 2024
Jason Campagna	Chief Medical Officer	$1,221,995			Mixed	24 Feb 2025
Atlas Venture Fund X, L.P.	10%+ Owner	$1,194,801			Mixed	25 Mar 2024
Jodie Pope Morrison	CEO, Director	$1,052,455	-$141,445	-12%	Mixed	25 Feb 2026
Shelia M. Violette	Chief Scientific Officer	$615,686	-$18,093	-2.9%	Mixed	25 Feb 2026
Lee Kalowski	CFO and President	$424,558	-$57,067	-12%	Mixed	25 Feb 2026
Timothy P. Kelly	Chief Operating Officer	$383,965			Mixed	24 Feb 2022
Iwicki Mark T.	Director	$342,666			Mixed	23 Oct 2025
Steven Gillis	Director	$308,660			Mixed	14 Jun 2023
Matthew R. Patterson	Director	$308,660			Mixed	14 Jun 2023
Jeffrey V Poulton	Director	$308,660			Mixed	14 Jun 2023
Alise Reicin	Director	$308,660			Mixed	14 Jun 2023
Richard J. Gregory	Director	$241,560			Mixed	15 Jun 2022
Kush Parmar	Director	$241,560			Mixed	15 Jun 2022
Arthur Tzianabos	Director	$171,333			Mixed	23 Oct 2025
Mary Thistle	Director	$171,333			Mixed	23 Oct 2025
Diyong Xu	Director	$171,333			Mixed	23 Oct 2025
Albert Seymour	President and Chief Executive Officer, Director	$96,184			Mixed	06 Sep 2023
Kathleen Laporte	Director	$63,998			Mixed	15 Jan 2026
Sven Ante Lundberg	Director	$55,998			Mixed	15 Jan 2026
David S. Grayzel	Director	$44,998			Mixed	15 Jan 2026
Isaac Manke	Director	$35,254			Mixed	23 Oct 2025
Gabriel Cohn	Chief Medical Officer	$11,506			Mixed	01 Jan 2022
Julie Jordan	Chief Medical Officer	$4,243			Mixed	03 Aug 2023
Paul Alloway	Former President and Chief Operating Officer of Homology Medicines, Inc.	$1,483			Mixed	25 Mar 2024
Charles Michaud Jr.	Former Vice President, Corporate Controller and Treasurer of Homology Medicines, Inc.	$529			Mixed	25 Mar 2024

Top shareholders of Q32 Bio Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ORBIMED ADVISORS LLC	13F 13D/G 3/4/5	Company · Director, 10%+ Owner	13% from 13D/G	2,252,987	$14,464,177	—	31 Mar 2026	13F 13D/G 3/4/5
Atlas Venture Life Science Advisors, LLC	13F	Company	12%	2,092,106	$13,431,321	—	31 Mar 2026	13F
Sirenia Capital Management LP	13D/G	—	9.9%	2,057,308	$12,138,117	$0	31 Mar 2026	13D/G
Opaleye Management Inc.	13F 13D/G	Company	8.6% from 13D/G	1,256,228	$8,064,984	—	31 Mar 2026	13F 13D/G
Carlyle Group Inc.	13F	Company	6.6%	1,102,741	$7,079,597	—	31 Mar 2026	13F
Point72 Asset Management, L.P.	13D/G	—	5.7%	958,768	$5,656,731	-$6,481,386	31 Mar 2026	13D/G
W. Bradford Smith	3/4/5	Chief Financial and Business Officer and Treasurer	— mixed-class rows	249,000 mixed-class rows	$2,899,867	—	23 Feb 2023	3/4/5
ARCH Venture Management, LLC	13F	Company	1.9%	320,482	$2,057,494	—	31 Mar 2026	13F
ACORN CAPITAL ADVISORS, LLC	13F	Company	1.9%	315,052	$2,022,634	—	31 Mar 2026	13F
VANGUARD CAPITAL MANAGEMENT LLC	13F	Company	1.8%	306,401	$1,967,094	—	31 Mar 2026	13F
MACKENZIE FINANCIAL CORP	13F	Company	1.5%	246,304	$1,581,272	—	31 Mar 2026	13F
Sanofi	13F	Company	1.5%	244,083	$1,567,013	—	31 Mar 2026	13F
Michael L. Blum	3/4/5	Chief Commercial Officer	— mixed-class rows	121,000 mixed-class rows	$1,415,233	—	23 Feb 2023	3/4/5
RENAISSANCE TECHNOLOGIES LLC	13F	Company	1.2%	206,915	$1,328,394	—	31 Mar 2026	13F
Jason Campagna	3/4/5	Chief Medical Officer	— mixed-class rows	108,187 mixed-class rows	$1,221,995	—	24 Feb 2025	3/4/5
Atlas Venture Fund X, L.P.	3/4/5	10%+ Owner	— class O/S missing	2,092,106	$1,194,801	—	25 Mar 2024	3/4/5
ACADIAN ASSET MANAGEMENT LLC	13F	Company	1%	172,586	$1,106,000	—	31 Mar 2026	13F
Jodie Pope Morrison	3/4/5	CEO, Director	1.3%	221,104	$1,052,455	-$141,445	25 Feb 2026	3/4/5
PFIZER INC	13D/G 13F	Pfizer Inc. (IRS Identification No.: 13-5315170) · Company	2.3%	277,777	$994,442	$0	31 Dec 2024	13D/G 13F
MONIMUS CAPITAL MANAGEMENT, LP	13F	Company	0.8%	134,310	$862,270	—	31 Mar 2026	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.7%	118,152	$758,740	—	31 Mar 2026	13F
Shelia M. Violette	3/4/5	Chief Scientific Officer	0.77%	129,346	$615,686	-$18,093	25 Feb 2026	3/4/5
BlackRock, Inc.	13F	Company	0.51%	86,147	$553,063	—	31 Mar 2026	13F
Lee Kalowski	3/4/5	CFO and President	0.53%	89,193	$424,558	-$57,067	25 Feb 2026	3/4/5
JANE STREET GROUP, LLC	13F	Company	0.39%	65,599	$421,145	—	31 Mar 2026	13F
Timothy P. Kelly	3/4/5	Chief Operating Officer	— mixed-class rows	33,000 mixed-class rows	$383,965	—	24 Feb 2022	3/4/5
Iwicki Mark T.	3/4/5	Director	— class O/S missing	53,521	$342,666	—	23 Oct 2025	3/4/5
MARSHALL WACE, LLP	13F	Company	0.31%	52,440	$336,664	—	31 Mar 2026	13F
VANGUARD FIDUCIARY TRUST CO	13F	Company	0.3%	49,995	$320,968	—	31 Mar 2026	13F
BRISTOL MYERS SQUIBB CO	13D/G	—	1.6%	200,244	$312,381	$0	31 Dec 2024	13D/G
Alise Reicin	3/4/5	Director	— class O/S missing	23,000	$308,660	—	14 Jun 2023	3/4/5
Jeffrey V Poulton	3/4/5	Director	— class O/S missing	23,000	$308,660	—	14 Jun 2023	3/4/5
Matthew R. Patterson	3/4/5	Director	— class O/S missing	23,000	$308,660	—	14 Jun 2023	3/4/5
Steven Gillis	3/4/5	Director	— class O/S missing	23,000	$308,660	—	14 Jun 2023	3/4/5
TWO SIGMA INVESTMENTS, LP	13F	Company	0.25%	42,346	$271,861	—	31 Mar 2026	13F
STATE STREET CORP	13F	Company	0.25%	41,514	$266,520	—	31 Mar 2026	13F
Kush Parmar	3/4/5	Director	— class O/S missing	18,000	$241,560	—	15 Jun 2022	3/4/5
Richard J. Gregory	3/4/5	Director	— class O/S missing	18,000	$241,560	—	15 Jun 2022	3/4/5
Cambridge Investment Research Advisors, Inc.	13F	Company	0.21%	35,025	$225,000	—	31 Mar 2026	13F
ADAR1 Capital Management, LLC	13F	Company	0.21%	35,000	$224,700	—	31 Mar 2026	13F
Affinity Asset Advisors, LLC	13F	Company	0.17%	27,777	$178,328	—	31 Mar 2026	13F
Arthur Tzianabos	3/4/5	Director	— class O/S missing	53,521	$171,333	—	23 Oct 2025	3/4/5
Diyong Xu	3/4/5	Director	— class O/S missing	53,521	$171,333	—	23 Oct 2025	3/4/5
Mary Thistle	3/4/5	Director	— class O/S missing	53,521	$171,333	—	23 Oct 2025	3/4/5
NORTHERN TRUST CORP	13F	Company	0.15%	25,033	$160,712	—	31 Mar 2026	13F
Cetera Investment Advisers	13F	Company	0.12%	20,695	$132,862	—	31 Mar 2026	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.11%	18,770	$120,503	—	31 Mar 2026	13F
CITADEL ADVISORS LLC	13F	Company	0.09%	15,481	$99,388	—	31 Mar 2026	13F
Albert Seymour	3/4/5	President and Chief Executive Officer, Director	— mixed-class rows	160,254 mixed-class rows	$96,184	—	06 Sep 2023	3/4/5
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.07%	12,613	$80,975	—	31 Mar 2026	13F

Recent Insider Transactions by Companies or Individuals for Q32 Bio Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Lee Kalowski	QTTB	Common Stock	Sale	-10%	$18,035	$4.51	-3,995	35,943	25 Feb 2026	Direct
Jodie Pope Morrison	QTTB	Common Stock	Sale	-10%	$44,674	$4.51	-9,896	89,104	25 Feb 2026	Direct
Shelia M. Violette	QTTB	Common Stock	Sale	-4.82%	$12,708	$4.51	-2,815	55,569	25 Feb 2026	Direct
Shelia M. Violette	QTTB	Common Stock	Award	67.5%			37,500	93,069	24 Feb 2026	Direct
Jodie Pope Morrison	QTTB	Common Stock	Award	148.1%			132,000	221,104	24 Feb 2026	Direct
Lee Kalowski	QTTB	Common Stock	Award	148.2%			53,250	89,193	24 Feb 2026	Direct
David S. Grayzel	QTTB	Stock Option (Right to Buy)	Award				16,363	16,363	15 Jan 2026	Direct
Sven Ante Lundberg	QTTB	Stock Option (Right to Buy)	Award				20,363	20,363	15 Jan 2026	Direct
Kathleen Laporte	QTTB	Stock Option (Right to Buy)	Award				23,272	23,272	15 Jan 2026	Direct
Jodie Pope Morrison	QTTB	Common Stock	Sale	-18.5%	$77,871	$3.46	-22,506	99,000	02 Dec 2025	Direct
Lee Kalowski	QTTB	Common Stock	Sale	-18.5%	$31,395	$3.46	-9,072	39,938	02 Dec 2025	Direct
Sven Ante Lundberg	QTTB	Stock Option (Right to Buy)	Award				53,521	53,521	23 Oct 2025	Direct
Iwicki Mark T.	QTTB	Stock Option (Right to Buy)	Award				53,521	53,521	23 Oct 2025	Direct
Isaac Manke	QTTB	Stock Option (Right to Buy)	Award				53,521	53,521	23 Oct 2025	Direct
Diyong Xu	QTTB	Stock Option (Right to Buy)	Award				53,521	53,521	23 Oct 2025	Direct
Mary Thistle	QTTB	Stock Option (Right to Buy)	Award				53,521	53,521	23 Oct 2025	Direct
David S. Grayzel	QTTB	Stock Option (Right to Buy)	Award				53,521	53,521	23 Oct 2025	Direct
Arthur Tzianabos	QTTB	Stock Option (Right to Buy)	Award				53,521	53,521	23 Oct 2025	Direct
Kathleen Laporte	QTTB	Stock Option (Right to Buy)	Award				53,521	53,521	23 Oct 2025	Direct
Jodie Pope Morrison	QTTB	Common Stock	Sale	-7.95%	$18,900	$1.80	-10,494	121,506	26 Aug 2025	Direct
Shelia M. Violette	QTTB	Common Stock	Sale	-4.87%	$5,385	$1.80	-2,990	58,384	26 Aug 2025	Direct
Lee Kalowski	QTTB	Common Stock	Sale	-7.96%	$7,636	$1.80	-4,240	49,010	26 Aug 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.